VIR BIOTECHNOLOGY, INC. (VIR): Price and Financial Metrics


0.23 (+0.77%)

POWR Rating

Component Grades













Add VIR to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where VIR ranks best; there it ranks ahead of 99.48% of US stocks.
  • VIR's strongest trending metric is Sentiment; it's been moving up over the last 177 days.
  • VIR ranks lowest in Momentum; there it ranks in the 5th percentile.

VIR Stock Summary

  • VIR's current price/earnings ratio is 3.48, which is higher than merely 5.13% of US stocks with positive earnings.
  • In terms of twelve month growth in earnings before interest and taxes, VIR BIOTECHNOLOGY INC is reporting a growth rate of -1,526.61%; that's higher than just 0.9% of US stocks.
  • Revenue growth over the past 12 months for VIR BIOTECHNOLOGY INC comes in at 736.56%, a number that bests 98.5% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to VIR BIOTECHNOLOGY INC, a group of peers worth examining would be ANAB, CARA, PRTA, RCUS, and IMTX.
  • VIR's SEC filings can be seen here. And to visit VIR BIOTECHNOLOGY INC's official web site, go to

VIR Valuation Summary

  • In comparison to the median Healthcare stock, VIR's price/earnings ratio is 84.62% lower, now standing at 3.4.
  • Over the past 40 months, VIR's price/sales ratio has gone down 142.2.

Below are key valuation metrics over time for VIR.

Stock Date P/S P/B P/E EV/EBIT
VIR 2023-01-30 1.6 1.8 3.4 2.1
VIR 2023-01-27 1.7 1.9 3.6 2.2
VIR 2023-01-26 1.7 1.9 3.5 2.2
VIR 2023-01-25 1.7 1.9 3.6 2.2
VIR 2023-01-24 1.7 1.9 3.5 2.2
VIR 2023-01-23 1.6 1.8 3.4 2.1

VIR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VIR has a Quality Grade of C, ranking ahead of 70.08% of graded US stocks.
  • VIR's asset turnover comes in at 0.18 -- ranking 205th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows VIR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.180 0.994 -1.000
2021-03-31 0.079 1.000 -1.298
2020-12-31 0.101 1.000 -1.042
2020-09-30 0.116 1.000 -0.987
2020-06-30 0.144 1.000 -0.971
2019-12-31 0.023 1.000 -1.077

VIR Price Target

For more insight on analysts targets of VIR, see our VIR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $69.86 Average Broker Recommendation 1.69 (Moderate Buy)

VIR Stock Price Chart Interactive Chart >

Price chart for VIR

VIR Price/Volume Stats

Current price $30.14 52-week high $34.97
Prev. close $29.91 52-week low $18.05
Day low $29.35 Volume 859,700
Day high $30.95 Avg. volume 781,609
50-day MA $26.92 Dividend yield N/A
200-day MA $24.90 Market Cap 4.01B


Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA.

VIR Latest News Stream

Event/Time News Detail
Loading, please wait...

VIR Latest Social Stream

Loading social stream, please wait...

View Full VIR Social Stream

Latest VIR News From Around the Web

Below are the latest news stories about VIR BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate VIR as an investment opportunity.

The 7 Most Undervalued Biotech Stocks to Buy in February 2023

Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.

Josh Enomoto on InvestorPlace | February 2, 2023

7 Healthcare Stocks That Will Be Big Winners in 2023

Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider.

Alex Sirois on InvestorPlace | January 31, 2023

'You have to have the goods': Retiring Vir CEO George Scangos looks back on building great companies

He built companies across cancer, spinal muscular atrophy and an accelerate treatment for Covid-19 and, potentially, other major infectious diseases at three multibillion-dollar drug developers. Now he's handing Vir's reins to outgoing Bayer exec Marianne De Backer.

Yahoo | January 25, 2023

Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor

– Dr. De Backer to assume CEO role on April 3, 2023 – – Upon his retirement as CEO, Dr. Scangos will transition to an advisory role through June 2, 2023 and will continue providing strategic counsel to Vir as a member of the Board of Directors – SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer (CEO), effective April 3, 2023. The Company’s Board of Directors h

Yahoo | January 25, 2023

Vir Biotechnology, Inc. (VIR) Moves to Strong Buy: Rationale Behind the Upgrade

Vir Biotechnology, Inc. (VIR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | January 24, 2023

Read More 'VIR' Stories Here

VIR Price Returns

1-mo 15.70%
3-mo 12.30%
6-mo -1.66%
1-year -9.81%
3-year 47.24%
5-year N/A
YTD 19.08%
2022 -39.55%
2021 56.35%
2020 112.96%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6446 seconds.